Share Price and Basic Stock Data
Last Updated: November 19, 2025, 10:57 pm
| PEG Ratio | 2.73 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Vimta Labs Ltd, operating in the Medical Research Services industry, reported a current market capitalization of ₹2,790 Cr with a share price of ₹625. The company has shown a robust sales trajectory, increasing from ₹276 Cr in March 2022 to ₹315 Cr by March 2023. In the trailing twelve months (TTM), sales stood at ₹384 Cr, indicating a significant growth trend. Quarterly sales figures reflect variability, with a peak of ₹82 Cr in June 2023 and a notable decline to ₹64 Cr in September 2023. Despite this fluctuation, the overall annual growth remains positive, suggesting that Vimta Labs is effectively capitalizing on its market opportunities. The company’s operating profit margins (OPM) have consistently hovered around 30% to 35%, with the latest figure for March 2025 recorded at 35%. This profitability level positions Vimta above many peers in the medical research sector, which typically averages lower margins.
Profitability and Efficiency Metrics
Vimta Labs has demonstrated solid profitability, with a net profit of ₹79 Cr and a return on equity (ROE) standing at 19.4%. The operating profit for the year ending March 2025 was reported at ₹122 Cr, reflecting a strong operational performance. The interest coverage ratio (ICR) is exceptionally high at 42.79x, indicating robust earnings relative to interest obligations. This is well above typical sector standards, showcasing Vimta’s strong financial health and ability to manage its debt efficiently. However, the cash conversion cycle (CCC) of 235 days raises concerns about operational efficiency, as it indicates a longer period to convert investments in inventory and receivables into cash. The company has room for improvement in reducing this cycle, especially as it relates to inventory management, which stood at 210 days for March 2025.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vimta Labs reveals a strong financial position with no reported borrowings, which is a significant advantage in maintaining financial flexibility. The company’s debt-to-equity ratio is an impressive 0.06, indicating minimal leverage and a conservative approach to financing. The book value per share has increased to ₹144.20 as of March 2024, reflecting a solid accumulation of shareholder value. The price-to-book value (P/BV) ratio stands at 3.08x, suggesting that the market values Vimta Labs at a premium compared to its book value, which can be indicative of investor confidence in future growth. However, the company must continue to enhance its capital efficiency, as evidenced by the return on capital employed (ROCE) which stood at 25% for March 2025, although this is still competitive within the industry standards.
Shareholding Pattern and Investor Confidence
The shareholding structure of Vimta Labs indicates a diversified ownership model. Promoters hold 36.67% of the shares as of June 2025, showcasing a stable management presence. Foreign institutional investors (FIIs) have increased their stake to 4.33%, reflecting growing interest from international investors. Meanwhile, domestic institutional investors (DIIs) hold a smaller portion at 0.87%, which may suggest limited institutional confidence. The public shareholding segment has risen to 58.80%, indicating strong retail investor support. The total number of shareholders has surged to 55,933, which reflects a growing interest in the company. This increased retail participation can be seen as a positive signal of investor confidence, although the declining share of promoter holdings over time may raise questions about management’s commitment.
Outlook, Risks, and Final Insight
Looking ahead, Vimta Labs appears well-positioned to leverage its strong operational performance and profitability metrics. However, key risks include the volatility in quarterly sales, as observed in the recent dip to ₹64 Cr in September 2023, which could impact overall annual performance if trends persist. Additionally, the high cash conversion cycle poses a risk to liquidity and operational efficiency. The company must prioritize strategies to enhance inventory turnover and receivables collection. On the positive side, Vimta’s strong balance sheet and minimal debt provide a cushion against market fluctuations. If the company can effectively manage its operational challenges while capitalizing on growth opportunities in the medical research sector, it could continue to attract investor interest and strengthen its market position further.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Vimta Labs Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Choksi Laboratories Ltd | 97.1 Cr. | 139 | 237/59.2 | 58.5 | 35.2 | 0.00 % | 9.20 % | 6.63 % | 10.0 |
| Vimta Labs Ltd | 2,790 Cr. | 625 | 903/362 | 37.4 | 93.5 | 0.16 % | 25.2 % | 19.4 % | 2.00 |
| Industry Average | 2,790.00 Cr | 382.00 | 47.95 | 64.35 | 0.08% | 17.20% | 13.02% | 6.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 79 | 79 | 76 | 81 | 82 | 64 | 73 | 73 | 75 | 83 | 90 | 94 | 98 |
| Expenses | 55 | 54 | 55 | 57 | 58 | 48 | 50 | 47 | 49 | 54 | 57 | 61 | 64 |
| Operating Profit | 24 | 25 | 21 | 24 | 24 | 17 | 23 | 26 | 26 | 29 | 33 | 33 | 34 |
| OPM % | 30% | 32% | 27% | 29% | 29% | 26% | 31% | 36% | 35% | 35% | 37% | 35% | 35% |
| Other Income | 1 | 1 | 1 | 1 | 1 | 0 | -1 | -1 | -1 | -1 | 5 | 2 | 2 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
| Depreciation | 7 | 8 | 8 | 8 | 8 | 9 | 8 | 8 | 8 | 8 | 10 | 9 | 10 |
| Profit before tax | 17 | 18 | 14 | 16 | 16 | 8 | 13 | 16 | 17 | 19 | 28 | 25 | 25 |
| Tax % | 27% | 26% | 27% | 23% | 25% | 25% | 25% | 24% | 26% | 24% | 23% | 27% | 25% |
| Net Profit | 12 | 13 | 10 | 12 | 12 | 6 | 9 | 12 | 12 | 15 | 22 | 18 | 19 |
| EPS in Rs | 2.72 | 2.95 | 2.25 | 2.77 | 2.63 | 1.34 | 2.14 | 2.79 | 2.77 | 3.29 | 4.84 | 4.12 | 4.24 |
Last Updated: August 1, 2025, 9:25 am
Below is a detailed analysis of the quarterly data for Vimta Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 98.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2025) to 98.00 Cr., marking an increase of 4.00 Cr..
- For Expenses, as of Jun 2025, the value is 64.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 61.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 33.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 35.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 35.00%.
- For Other Income, as of Jun 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 2.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Mar 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 27.00% (Mar 2025) to 25.00%, marking a decrease of 2.00%.
- For Net Profit, as of Jun 2025, the value is 19.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Mar 2025) to 19.00 Cr., marking an increase of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.24. The value appears strong and on an upward trend. It has increased from 4.12 (Mar 2025) to 4.24, marking an increase of 0.12.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 4:10 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 289 | 344 | 384 |
| Expenses | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 195 | 222 | 250 |
| Operating Profit | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 94 | 122 | 134 |
| OPM % | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 33% | 35% | 35% |
| Other Income | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | -4 | 5 | 11 |
| Interest | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 | 2 | 2 |
| Depreciation | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 33 | 35 | 39 |
| Profit before tax | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 55 | 90 | 104 |
| Tax % | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | 25% | 25% | |
| Net Profit | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 41 | 67 | 79 |
| EPS in Rs | 3.00 | 1.14 | 1.45 | 2.40 | 3.72 | 5.73 | 1.57 | 4.81 | 9.29 | 10.68 | 9.26 | 15.13 | 17.67 |
| Dividend Payout % | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% | 11% | 7% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -61.54% | 20.00% | 83.33% | 45.45% | 56.25% | -72.00% | 200.00% | 95.24% | 14.63% | -12.77% | 63.41% |
| Change in YoY Net Profit Growth (%) | 0.00% | 81.54% | 63.33% | -37.88% | 10.80% | -128.25% | 272.00% | -104.76% | -80.60% | -27.40% | 76.18% |
Vimta Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| TTM: | 28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 58% |
| 3 Years: | 17% |
| TTM: | 51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 72% |
| 3 Years: | 65% |
| 1 Year: | 146% |
| Return on Equity | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 17% |
| 3 Years: | 17% |
| Last Year: | 19% |
Last Updated: September 5, 2025, 1:51 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 | 110 | 113 |
| Inventory Days | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 154 | 195 | 260 | 210 |
| Days Payable | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 108 | 124 | 87 | 88 |
| Cash Conversion Cycle | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 147 | 164 | 283 | 235 |
| Working Capital Days | 65 | 109 | 99 | 22 | 62 | 78 | 64 | 89 | 87 | 78 | 98 | 96 |
| ROCE % | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% | 20% | 25% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 330,152 | 0.1 | 14.99 | 330,152 | 2025-04-22 17:25:16 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 78 | 0.04 | 0 | 78 | 2025-04-22 17:25:16 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 18.51 | 21.77 | 18.70 | 9.68 | 3.10 |
| Diluted EPS (Rs.) | 18.24 | 21.35 | 18.32 | 9.68 | 3.10 |
| Cash EPS (Rs.) | 33.92 | 35.65 | 29.24 | 20.12 | 12.56 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 144.20 | 127.33 | 105.83 | 87.92 | 78.19 |
| Revenue From Operations / Share (Rs.) | 143.55 | 143.78 | 125.86 | 95.29 | 81.73 |
| PBDIT / Share (Rs.) | 40.96 | 44.44 | 36.97 | 24.33 | 14.91 |
| PBIT / Share (Rs.) | 25.53 | 30.57 | 26.42 | 13.89 | 5.44 |
| PBT / Share (Rs.) | 24.57 | 29.37 | 25.19 | 12.91 | 3.74 |
| Net Profit / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| NP After MI And SOA / Share (Rs.) | 18.50 | 21.77 | 18.69 | 9.68 | 3.10 |
| PBDIT Margin (%) | 28.52 | 30.91 | 29.37 | 25.52 | 18.24 |
| PBIT Margin (%) | 17.78 | 21.25 | 20.98 | 14.57 | 6.65 |
| PBT Margin (%) | 17.11 | 20.42 | 20.01 | 13.54 | 4.57 |
| Net Profit Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| NP After MI And SOA Margin (%) | 12.88 | 15.13 | 14.85 | 10.16 | 3.78 |
| Return on Networth / Equity (%) | 12.82 | 17.09 | 17.66 | 11.01 | 3.95 |
| Return on Capital Employeed (%) | 16.36 | 22.17 | 22.51 | 13.92 | 6.39 |
| Return On Assets (%) | 10.25 | 13.29 | 13.45 | 7.80 | 2.78 |
| Long Term Debt / Equity (X) | 0.02 | 0.03 | 0.05 | 0.07 | 0.03 |
| Total Debt / Equity (X) | 0.06 | 0.05 | 0.08 | 0.11 | 0.13 |
| Asset Turnover Ratio (%) | 0.83 | 0.95 | 0.95 | 0.81 | 0.00 |
| Current Ratio (X) | 2.91 | 2.86 | 2.60 | 2.05 | 1.67 |
| Quick Ratio (X) | 2.46 | 2.46 | 2.24 | 1.78 | 1.37 |
| Dividend Payout Ratio (NP) (%) | 10.79 | 9.17 | 10.69 | 0.00 | 64.60 |
| Dividend Payout Ratio (CP) (%) | 5.88 | 5.60 | 6.83 | 0.00 | 15.91 |
| Earning Retention Ratio (%) | 89.21 | 90.83 | 89.31 | 0.00 | 35.40 |
| Cash Earning Retention Ratio (%) | 94.12 | 94.40 | 93.17 | 0.00 | 84.09 |
| Interest Coverage Ratio (X) | 42.79 | 37.19 | 54.56 | 24.81 | 8.76 |
| Interest Coverage Ratio (Post Tax) (X) | 20.33 | 19.21 | 29.41 | 10.87 | 2.82 |
| Enterprise Value (Cr.) | 979.08 | 670.65 | 704.61 | 372.30 | 147.42 |
| EV / Net Operating Revenue (X) | 3.08 | 2.11 | 2.53 | 1.77 | 0.81 |
| EV / EBITDA (X) | 10.78 | 6.82 | 8.62 | 6.92 | 4.47 |
| MarketCap / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| Retention Ratios (%) | 89.20 | 90.82 | 89.30 | 0.00 | 35.39 |
| Price / BV (X) | 3.08 | 2.47 | 2.98 | 1.83 | 0.75 |
| Price / Net Operating Revenue (X) | 3.10 | 2.19 | 2.50 | 1.69 | 0.72 |
| EarningsYield | 0.04 | 0.06 | 0.05 | 0.06 | 0.05 |
After reviewing the key financial ratios for Vimta Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 18.51. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.51, marking a decrease of 3.26.
- For Diluted EPS (Rs.), as of Mar 24, the value is 18.24. This value is within the healthy range. It has decreased from 21.35 (Mar 23) to 18.24, marking a decrease of 3.11.
- For Cash EPS (Rs.), as of Mar 24, the value is 33.92. This value is within the healthy range. It has decreased from 35.65 (Mar 23) to 33.92, marking a decrease of 1.73.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 144.20. It has increased from 127.33 (Mar 23) to 144.20, marking an increase of 16.87.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.55. It has decreased from 143.78 (Mar 23) to 143.55, marking a decrease of 0.23.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 40.96. This value is within the healthy range. It has decreased from 44.44 (Mar 23) to 40.96, marking a decrease of 3.48.
- For PBIT / Share (Rs.), as of Mar 24, the value is 25.53. This value is within the healthy range. It has decreased from 30.57 (Mar 23) to 25.53, marking a decrease of 5.04.
- For PBT / Share (Rs.), as of Mar 24, the value is 24.57. This value is within the healthy range. It has decreased from 29.37 (Mar 23) to 24.57, marking a decrease of 4.80.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 18.50. This value is within the healthy range. It has decreased from 21.77 (Mar 23) to 18.50, marking a decrease of 3.27.
- For PBDIT Margin (%), as of Mar 24, the value is 28.52. This value is within the healthy range. It has decreased from 30.91 (Mar 23) to 28.52, marking a decrease of 2.39.
- For PBIT Margin (%), as of Mar 24, the value is 17.78. This value is within the healthy range. It has decreased from 21.25 (Mar 23) to 17.78, marking a decrease of 3.47.
- For PBT Margin (%), as of Mar 24, the value is 17.11. This value is within the healthy range. It has decreased from 20.42 (Mar 23) to 17.11, marking a decrease of 3.31.
- For Net Profit Margin (%), as of Mar 24, the value is 12.88. This value exceeds the healthy maximum of 10. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 12.88. This value is within the healthy range. It has decreased from 15.13 (Mar 23) to 12.88, marking a decrease of 2.25.
- For Return on Networth / Equity (%), as of Mar 24, the value is 12.82. This value is below the healthy minimum of 15. It has decreased from 17.09 (Mar 23) to 12.82, marking a decrease of 4.27.
- For Return on Capital Employeed (%), as of Mar 24, the value is 16.36. This value is within the healthy range. It has decreased from 22.17 (Mar 23) to 16.36, marking a decrease of 5.81.
- For Return On Assets (%), as of Mar 24, the value is 10.25. This value is within the healthy range. It has decreased from 13.29 (Mar 23) to 10.25, marking a decrease of 3.04.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.02. This value is below the healthy minimum of 0.2. It has decreased from 0.03 (Mar 23) to 0.02, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.06. This value is within the healthy range. It has increased from 0.05 (Mar 23) to 0.06, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.83. It has decreased from 0.95 (Mar 23) to 0.83, marking a decrease of 0.12.
- For Current Ratio (X), as of Mar 24, the value is 2.91. This value is within the healthy range. It has increased from 2.86 (Mar 23) to 2.91, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 2.46. This value exceeds the healthy maximum of 2. There is no change compared to the previous period (Mar 23) which recorded 2.46.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 10.79. This value is below the healthy minimum of 20. It has increased from 9.17 (Mar 23) to 10.79, marking an increase of 1.62.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 5.88. This value is below the healthy minimum of 20. It has increased from 5.60 (Mar 23) to 5.88, marking an increase of 0.28.
- For Earning Retention Ratio (%), as of Mar 24, the value is 89.21. This value exceeds the healthy maximum of 70. It has decreased from 90.83 (Mar 23) to 89.21, marking a decrease of 1.62.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 94.12. This value exceeds the healthy maximum of 70. It has decreased from 94.40 (Mar 23) to 94.12, marking a decrease of 0.28.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 42.79. This value is within the healthy range. It has increased from 37.19 (Mar 23) to 42.79, marking an increase of 5.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 20.33. This value is within the healthy range. It has increased from 19.21 (Mar 23) to 20.33, marking an increase of 1.12.
- For Enterprise Value (Cr.), as of Mar 24, the value is 979.08. It has increased from 670.65 (Mar 23) to 979.08, marking an increase of 308.43.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.11 (Mar 23) to 3.08, marking an increase of 0.97.
- For EV / EBITDA (X), as of Mar 24, the value is 10.78. This value is within the healthy range. It has increased from 6.82 (Mar 23) to 10.78, marking an increase of 3.96.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For Retention Ratios (%), as of Mar 24, the value is 89.20. This value exceeds the healthy maximum of 70. It has decreased from 90.82 (Mar 23) to 89.20, marking a decrease of 1.62.
- For Price / BV (X), as of Mar 24, the value is 3.08. This value exceeds the healthy maximum of 3. It has increased from 2.47 (Mar 23) to 3.08, marking an increase of 0.61.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 3.10. This value exceeds the healthy maximum of 3. It has increased from 2.19 (Mar 23) to 3.10, marking an increase of 0.91.
- For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 23) to 0.04, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vimta Labs Ltd:
- Net Profit Margin: 12.88%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.36% (Industry Average ROCE: 17.2%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.82% (Industry Average ROE: 13.02%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 20.33
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.4 (Industry average Stock P/E: 47.95)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 12.88%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Research Services | Plot Nos. 141/2 & 142, Hyderabad Telangana 500051 | shares@vimta.com http://www.vimta.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Sivalinga Prasad Vasireddi | Executive Chairman |
| Ms. Harita Vasireddi | Managing Director |
| Mr. Harriman Vungal | Executive Director - Operations |
| Mr. Satya Sreenivas Neerukonda | Executive Director |
| Dr. Yadagiri R Pendri | Independent Director |
| Ms. Prameela Rani Yalamanchili | Independent Director |
| Mr. Sanjay Dave | Independent Director |
| Mr. Purnachandra Rao Gutta | Independent Director |